Roche’s acquisition of Denmark’s venture capital-backed Roche Innovation Center Copenhagen AS suggests rehabilitation of RNA-targeting technology in the biotech community is a fact. The transaction also may help European venture capitalists (VCs) attract extra funds to invest in biotech.
Roche announced it was buying Santaris for an upfront of $250 million and $200 million in contingent payments on Aug....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?